# Hypertension in Breast Cancer Patients Receiving Bevacizumab

> **NCT00674011** · — · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 10 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00674011
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2014-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00674011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00674011, "Hypertension in Breast Cancer Patients Receiving Bevacizumab". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00674011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*